ESC 365 - Controversies in the management of pulmonary hypertension and venous thromboembolism

ESC Premium Access

Controversies in the management of pulmonary hypertension and venous thromboembolism

Event: ESC CONGRESS 2019

Topic: Treatment

Session type: Debate Session

Date: 1 September 2019

Time: 11:00 - 12:30

Session

6 presentations in this session

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - PRO

Speaker: Professor L. Mazzolai (Lausanne, CH)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - CON

Speaker: Professor N. Meneveau (Besancon, FR)

Lifelong anticoagulation is the best option after unprovoked venous thromboembolism - Discussion

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - PRO

Speaker: Professor S. Rosenkranz (Cologne, DE)

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - CON

Speaker: Doctor J. Bermejo Thomas (Madrid, ES)

Pulmonary hypertension due to left heart disease should be treated with drugs approved for idiopathic pulmonary arterial hypertension - Discussion

4 speakers from this session

Professor Lucia Mazzolai

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

9 presentations

0 follower

Professor Nicolas Meneveau

University Hospital of Besancon - Hospital Jean Minjoz, Besancon (France)

9 presentations

0 follower

Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)

19 presentations

0 follower

Doctor Javier Bermejo Thomas

University Hospital Gregorio Maranon, Madrid (Spain)

4 presentations

0 follower

This platform is supported by